SecBot SecBot
DEFA14A ·Filed Apr 23, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001140361-26-016373
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the company's proxy statement and 10-K for details on the proposed share increase in the stock incentive plan, as this could impact future dilution. The outcome of these votes is expected to be routine with management recommendations likely to pass.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.94
T+0 close · Apr 23, 2026 · via day close
Latest settled
+5.37%
T+60 · $9.42
Vs SPY
+0.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $8.94entry
  2. T+1 · 7mo ago −0.45%α −0.61% · $8.90
  3. T+5 · 7mo ago +2.46%α +1.55% · $9.16
  4. T+20 · 6mo ago −6.38%α −10.40% · $8.37
  5. T+60 · 4mo ago +5.37%α +0.29% · $9.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst Pharmaceuticals is holding its 2026 annual meeting to vote on several proposals, including the election of three directors, ratification of auditors, an advisory vote on executive compensation, and approval of an amended stock incentive plan to increase shares available for issuance. This is a routine annual shareholder meeting with no activist involvement or contested issues.

Key Financial Metrics

Vote
director election
Meeting
2026-06-11

Key Facts

  • Annual meeting scheduled for June 11, 2026
  • Three director nominees: Theresa M. Heggie, Amy E. McKee, M.D., and Jon P. Stonehouse
  • Proposal to ratify Ernst & Young LLP as independent auditors
  • Advisory vote on executive compensation
  • Proposal to amend and restated Stock Incentive Plan to increase shares available for issuance

Financial Impact

Approval of the amended Stock Incentive Plan would increase dilution potential, but no specific share count or financial impact is disclosed in this filing

dilutionexecutive compensation

Risk Factors

  • Potential dilution from approval of additional shares in the stock incentive plan
  • Shareholder opposition to executive compensation if deemed excessive

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-016373
Document: 0001140361-26-016373-index-headers.html0001140361-26-016373
Document: 0001140361-26-016373-index.html0001140361-26-016373
Document: 0001140361-26-016373.txt0001140361-26-016373

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026